Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level904 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02734160 | A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer | completed | Phase 1 | 37 | Eli Lilly and CompanyINDUSTRY | 5 | Aug 5, 2019 | clinicaltrials |
| NCT02707328 | Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002) | terminated | Phase 1 | 30 | The Cooper Health SystemOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01739439 | Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery | terminated | Phase 1 | 6 | Fox Chase Cancer CenterOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT03778879 | Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B | withdrawn | Phase 1 / Phase 2 | 0 | Alan KatzOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT01858883 | Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 55 | Incyte CorporationINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02973672 | Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas | completed | Phase 1 / Phase 2 | 75 | SurgimabINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02283372 | Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer | completed | Phase 1 | 30 | Washington University School of MedicineOTHER | 1 | Jun 19, 2019 | clinicaltrials |
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Hitendra PatelOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT03797443 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Piedmont Cancer InstituteOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Medical College of WisconsinOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT01893801 | Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA | completed | Phase 1 / Phase 2 | 25 | Pancreatic Cancer Research TeamOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT03941457 | Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 9 | Asclepius Technology Company Group (Suzhou) Co., Ltd.INDUSTRY | 1 | May 8, 2019 | clinicaltrials |
| NCT01128296 | Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas | completed | Phase 1 / Phase 2 | 35 | Amer ZureikatOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT02581501 | Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer | withdrawn | Phase 1 | 0 | Stamford HospitalOTHER | 1 | Apr 18, 2019 | clinicaltrials |
| NCT00923299 | Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine(THERAPY) | completed | Phase 1 / Phase 2 | 33 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00968604 | C-VISA BikDD: Liposome in Advanced Pancreatic Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 11, 2019 | clinicaltrials |
| NCT01537107 | Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 31 | Mayo ClinicOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT02868632 | Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer | withdrawn | Phase 1 | 0 | NYU Langone HealthOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02782182 | Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study | terminated | Phase 1 | 1 | University of ChicagoOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01984658 | A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients | completed | Phase 1 | 10 | CytoVac A/SINDUSTRY | 1 | Feb 26, 2019 | clinicaltrials |
| NCT01025882 | Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer | terminated | Phase 1 | 5 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT02433626 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies(COTI2-101) | unknown | Phase 1 | 51 | Critical Outcome Technologies Inc.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02548169 | Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer(PancVax) | terminated | Phase 1 | 7 | Baylor Research InstituteOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT00438256 | Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01632306 | A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT03634501 | Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells | unknown | Phase 1 / Phase 2 | 200 | Xuanwu Hospital, BeijingOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT01286987 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 113 | PfizerINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 124 | Pharmacyclics LLC.INDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT01839981 | CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 1 | 10 | Wake Forest University Health SciencesOTHER | 1 | Dec 27, 2018 | clinicaltrials |
| NCT01770132 | Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer | completed | Phase 1 | 12 | John DeWittOTHER | 1 | Dec 13, 2018 | clinicaltrials |
| NCT00310050 | Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer | terminated | Phase 1 | 4 | Wake Forest University Health SciencesOTHER | 1 | Nov 30, 2018 | clinicaltrials |
| NCT01453153 | Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer | completed | Phase 1 / Phase 2 | 28 | Halozyme TherapeuticsINDUSTRY | 2 | Nov 30, 2018 | clinicaltrials |
| NCT02960594 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse(TRT-001) | completed | Phase 1 | 93 | Inovio PharmaceuticalsINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT01833546 | A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer | completed | Phase 1 | 20 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 15, 2018 | clinicaltrials |
| NCT02045589 | A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | completed | Phase 1 | 8 | Theriva Biologics SLINDUSTRY | 1 | Oct 1, 2018 | clinicaltrials |
| NCT01663272 | A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer | completed | Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT02620423 | Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | completed | Phase 1 | 11 | Oncolytics BiotechINDUSTRY | 1 | Sep 13, 2018 | clinicaltrials |
| NCT02191761 | Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer | completed | Phase 1 | 13 | Biosplice Therapeutics, Inc.INDUSTRY | 1 | Sep 7, 2018 | clinicaltrials |
| NCT03662412 | Study of Sirolimus in Patients With Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 36 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00783172 | Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer | terminated | Phase 1 | 4 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 6, 2018 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT01621243 | M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 128 | Momenta Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 29, 2018 | clinicaltrials |
| NCT01456585 | Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma | completed | Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT02975141 | Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer(AFFECT) | unknown | Phase 1 | 12 | PD Dr. med. Volker HeinemannOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT02166255 | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 17 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT02331251 | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | terminated | Phase 1 / Phase 2 | 81 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00892736 | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | completed | Phase 1 | 98 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2019source: clinicaltrials